Aptevo Therapeutics Inc. (APVO)
| Bid | 0.5 |
| Market Cap | 2.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.13M |
| EPS (ttm) | -87.38 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.03 |
| Analyst | Buy |
| Ask | 0.5 |
| Volume | 391,230 |
| Avg. Volume (20D) | 2,935,180 |
| Open | 0.51 |
| Previous Close | 0.53 |
| Day's Range | 0.49 - 0.53 |
| 52-Week Range | 0.49 - 51.06 |
| Beta | 5.75 |
About APVO
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational ...
Analyst Forecast
According to 1 analyst ratings, the average rating for APVO stock is "Buy." The 12-month stock price forecast is $296, which is an increase of 59361.63% from the latest price.
Stock Forecasts
2 months ago · accessnewswire.com
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVMarvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth ORLANDO, FL / ACCESS Newswire / February 15, 2025 / RedChip Companies announced today that an interview with A...
2 months ago · accessnewswire.com
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% ...